JPRN-jRCT2080220292未知2 期
ate phase II study on dose response of SMP-508 therapy in patients with type 2 diabetes mellitus who are concomitantly taking alpha-glucosidase inhibitor
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes mellitus who satisfy the following inclusion criteria
- •-Patients who are taking alpha-glucosidase inhibitor in addition to diet and exercise therapies
- •-Patients whose HbA1c levels are 6.5%<=HbA1c<=9.0%, and are stable over 4 weeks
- •-Patients aged 20 or older
- •-Outpatients
- •-Patients with hepatic dysfunction
- •-Patients with renal dysfunction
- •-Patients with cardiac diseases or severe hypertension
排除标准
- 未提供
研究者
相似试验
未知
2 期
ate phase II study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitusType 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by diet and exercise therapiesJPRN-jRCT2080220179Dainippon Sumitomo Pharma Co., Ltd.
未知
3 期
Phase III study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitusJPRN-jRCT2080220511Dainippon Sumitomo Pharma Co., Ltd.
未知
3 期
Phase 3 study on combinational therapy of SMP-508 with metformin in patients with type 2 diabetes mellitusJPRN-jRCT2080221166Dainippon Sumitomo Pharma Co., Ltd.120
未知
3 期
Phase 3 study on combinational therapy of SMP-508 with pioglitazone in patients with type 2 diabetes mellitusType 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by pioglitazone in addition to diet and exercise therapiesJPRN-jRCT2080221168Dainippon Sumitomo Pharma Co., Ltd.120
已完成
不适用
A phase II dose-response study to assess the safety and efficacy of SJP-0035 in patients with corneal epithelial disorderCorneal epithelial disorderJPRN-UMIN000034199Senju Pharmaceutical Co.,Ltd.90